Fintel reports that Ra Capital Management has filed a 13D/A form with the SEC disclosing ownership of 7.66MM shares of DICE Therapeutics Inc (DICE). This represents 16.1% of the company.
In their previous filing dated October 19, 2022 they reported 6.85MM shares and 14.40% of the company, an increase in shares of 11.85% and an increase in total ownership of 1.70% (calculated as current – previous percent ownership).
Analyst Price Forecast Suggests 116.84% Upside
As of March 28, 2023, the average one-year price target for DICE Therapeutics is $63.97. The forecasts range from a low of $49.49 to a high of $80.85. The average price target represents an increase of 116.84% from its latest reported closing price of $29.50.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for DICE Therapeutics is $0MM. The projected annual non-GAAP EPS is -$2.70.
What is the Fund Sentiment?
There are 276 funds or institutions reporting positions in DICE Therapeutics. This is an increase of 59 owner(s) or 27.19% in the last quarter. Average portfolio weight of all funds dedicated to DICE is 0.45%, a decrease of 16.57%. Total shares owned by institutions increased in the last three months by 26.97% to 50,310K shares. The put/call ratio of DICE is 2.41, indicating a bearish outlook.
What are Large Shareholders Doing?
Northpond Ventures holds 3,293K shares representing 6.90% ownership of the company. No change in the last quarter.
Price T Rowe Associates holds 3,220K shares representing 6.75% ownership of the company. In it’s prior filing, the firm reported owning 2,553K shares, representing an increase of 20.70%. The firm increased its portfolio allocation in DICE by 90.49% over the last quarter.
Sands Capital Ventures holds 2,749K shares representing 5.76% ownership of the company. In it’s prior filing, the firm reported owning 3,149K shares, representing a decrease of 14.55%. The firm decreased its portfolio allocation in DICE by 99.87% over the last quarter.
Avoro Capital Advisors holds 2,526K shares representing 5.29% ownership of the company. In it’s prior filing, the firm reported owning 1,075K shares, representing an increase of 57.44%. The firm increased its portfolio allocation in DICE by 192.37% over the last quarter.
Driehaus Capital Management holds 1,954K shares representing 4.09% ownership of the company. In it’s prior filing, the firm reported owning 1,972K shares, representing a decrease of 0.93%. The firm increased its portfolio allocation in DICE by 50.09% over the last quarter.
DICE Therapeutics Background Information
(This description is provided by the company.)
DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
